Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

10.5%

2 terminated/withdrawn out of 19 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

26%

5 trials in Phase 3/4

Results Transparency

94%

15 of 16 completed trials have results

Key Signals

1 recruiting15 with results

Enrollment Performance

Analytics

Phase 2
6(37.5%)
Phase 1
5(31.3%)
Phase 3
4(25.0%)
Phase 4
1(6.3%)
16Total
Phase 2(6)
Phase 1(5)
Phase 3(4)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT04026178Phase 4Completed

Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

Role: lead

NCT02009345Recruiting

Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada

Role: collaborator

NCT01915771Phase 1Completed

Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects

Role: lead

NCT02080455Phase 1Completed

Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.

Role: lead

NCT02080468Phase 1Completed

Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

Role: lead

NCT01760187Phase 1Completed

Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C

Role: lead

NCT02173158Phase 3Completed

Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy

Role: lead

NCT00943306Phase 3Completed

Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

Role: lead

NCT00474240Phase 2Completed

AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia

Role: lead

NCT00730236Phase 3Completed

A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

Role: lead

NCT00559962Phase 2Completed

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

Role: lead

NCT00359281Phase 2Completed

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

Role: lead

NCT00690443Phase 2Completed

Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

Role: lead

NCT02765841Phase 3Withdrawn

Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy

Role: lead

NCT02044419Phase 1Completed

A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled

Role: lead

NCT02399852Withdrawn

Effects of Lomitapide on Carotid and Aortic Atherosclerosis

Role: lead

NCT02778646Completed

Detection of Familial Hypercholesterolaemia in Cardiovascular Disease Registry

Role: collaborator

NCT00405067Phase 2Completed

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

Role: lead

NCT01556906Phase 2Completed

Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor

Role: lead

All 19 trials loaded